Page 61 - Priority Review News Today

The FDA has approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

DelveInsights, Rett Syndrome Pipeline Insight 2023 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Rett Syndrome pipeline landscape. It covers the Rett... | May 2, 2023

TORONTO, May 02, 2023 -- PharmaTher Holdings Ltd. , a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration for... | May 2, 2023

BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an... | May 1, 2023

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...

Pfizer is planning a $470-million expansion of its Vaccine Research and Development facilities in Pearl River, NY.

Having extinguished all debt and significantly reduced cost-base, RedHill is now focused on late-stage pipeline advancement, in collaboration with U.S. and...

Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023...

Investegate announcements from Indivior PLC, 1st Quarter Results